Latest

Pfizer plans to slap Covid vaccine with a 10,000% markup when it hits the public market: report

October 27, 2022 | | Print Article

Big Pharma is reportedly soon to implement a big markup for the COVID-19 jab, boosting the booster by about 10,000 percent in a form of purported profiteering that one organization is describing as “daylight robbery.”

“Once the government uses up the doses it has already bought, Pfizer will hike the price to as much as $130 for a single dose of the vaccine which is estimated by some experts to cost just $1.18 to make,” the Daily Mail reported. “Analysts speculate that the move was made so Pfizer could still meet its target of $32 billion of projected vaccine revenue this year.”

The Biden administration has been paying the multinational pharmaceutical corporation a mere $20 or so for each shot that Americans have been receiving free of charge regardless of what kind of insurance coverage they may or may not have.

The Pfizer jab currently consists of a two-shot regimen. As mentioned above, the company is switching to a single dose, the development costs for which is the supposed reason for the price hike.

“The price would make the two-dose vaccine more expensive for cash-paying customers than annual flu shots,” the New York Post reported earlier this month.

Public health officials and the political and media establishment, from Joe Biden on down, have insisted that COVID vaccines are safe and effective.

Going forward, “Health insurers are expected to cover the cost of the [Pfizer] shots for those who have coverage, but Wall Street analysts warn that it will cause upward pressure on insurance premiums,” the news outlet added. “The People’s Vaccine Alliance (PVA) — a non-profit that campaigns for vaccine equity — described the price hike as a ‘daylight robbery.'”

For individual consumers depending on their circumstances, this scenario might mean an increase in out-of-pocket costs and perhaps higher deductibles.

“The drugmaker said it expects that people with private health insurance or coverage through public programs like Medicare or Medicaid will pay nothing. The Affordable Care Act requires insurers to cover many recommended vaccines without charging any out-of-pocket expense,” the New York Post asserted.

Pfizer also has set up an income assistance program for those eligible.

Peter Maybarduk, an official with Public Citizen, a nonprofit consumer advocacy organization, told the Daily Mail that Pfizer “has already made an ‘obscene’ amount of money, and will be ok if they do not meet revenue projections that were likely inflated anyways and… still has not said how they would guarantee access to shots to the 26 million uninsured Americans…Mr Maybarduk’s group’s report found that the mRNA vaccines could be produced for just over a dollar, a figure dwarfed by the figure Pfizer is charging for the shot.”

In the meantime, various Pfizer executives on an individual basis have reportedly made a fortune during the pandemic.

As alluded to above, “The vaccine brought in $36.78 billion in revenue last year for Pfizer and was the drugmaker’s top-selling product. Analysts predict that it will rack up another $32 billion this year, according to FactSet. But they also expect sales to fall rapidly after that,” the New York Post noted.

The U.S. Centers for Disease Control has recently recommended that school children across the country receive the jab, which in mandate-worshipping blue states is essentially accepted as gospel.

Various GOP governors have vowed that they will not implement the recommendation.

In a separate issue, under questioning from European Union Parliament member Rob Roos, a Pfizer executive reportedly admitted that the substance was never tested on a pre-market basis for its efficacy in preventing transmission of the COVID virus.

According to People magazine, however, the Roos clip spread misinformation on social media. “Pfizer never claimed to have conducted studies on the vaccine’s effect on transmission in its original clinical trials prior to the company’s COVID vaccine receiving emergency use authorization by the FDA in December 2020.”

A fact-checking website called Full Fact similarly indicated that “Pfizer was always clear it did not test whether the vaccines reduced the risk of transmission among already-infected individuals. But the trial did show the vaccines reduced infection risk in the first place, so reduced the risk of onward infection.”

In another matter, Pfizer is allegedly under investigation by authorities in Italy, Bloomberg reported on Wednesday.

“Pfizer Inc. is the target of an Italian probe alleging the company hid at least €1.2 billion ($1.2 billion) in profit by transferring money to units in other countries, according to people familiar with the investigation.”

Unidentified sources told Bloomberg that “Italy’s finance police have alleged that Pfizer’s unit based just outside Rome, Pfizer Italia Srl, transferred excess capital to affiliates in the US and the Netherlands to avoid taxes on profit that could be as high as 26%.”

Get the latest BPR news delivered free to your inbox daily. SIGN UP

DONATE TO BIZPAC REVIEW

Please help us! If you are fed up with letting radical big tech execs, phony fact-checkers, tyrannical liberals and a lying mainstream media have unprecedented power over your news please consider making a donation to BPR to help us fight them. Now is the time. Truth has never been more critical!

$10
$15
$25
$50
Other
$
Success! Thank you for donating. Please share BPR content to help combat the lies.
Robert Jonathan
Latest posts by Robert Jonathan (see all)

Comment

We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. If a comment is spam, instead of replying to it please click the ∨ icon below and to the right of that comment. Thank you for partnering with us to maintain fruitful conversation.

PLEASE JOIN OUR NEW COMMENT SYSTEM! We love hearing from our readers and invite you to join us for feedback and great conversation. If you've commented with us before, we'll need you to re-input your email address for this. The public will not see it and we do not share it.

Latest Articles